For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

The head of drugmaker Eli Lilly, which sells the popular ... tariffs currently in effect do not materially change Lilly’s 2025 financial outlook,” he said. “However, the expansion of tariffs ...

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Eli Lilly (LLY). But which of these two companies is the best option for those ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

There are significant questions on how the order can be implemented, and if companies can raise prices on already approved ...